Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Depreciation & Amortization (CF) (2024 - 2025)

Pyxis Oncology has reported Depreciation & Amortization (CF) over the past 2 years, most recently at $2.9 million for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 426.73% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, up 51.27% year-over-year, with the annual reading at $4.5 million for FY2025, 51.27% up from the prior year.
  • Depreciation & Amortization (CF) was $2.9 million for Q4 2025 at Pyxis Oncology, up from $527000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $2.9 million in Q4 2025 and troughed at $527000.0 in Q3 2025.